There was a hint that the drug might help turn some immune cells into a less inflammatory type, but the data weren’t strong enough to be sure.

Pro

Against

Evidence from Studies

Supporting (0)

Community contributions welcome

No supporting evidence found

Contradicting (1)

Community contributions welcome

A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice

Randomized Controlled Trial

Animal

2023

The study shows that the drug MPE-298 helps reduce plaque buildup in mice, but it never checked whether the immune cells in the plaques became more or less inflammatory, so we can't say if it supports the claim about cell ratios.

Source Study

A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice

Score: 12

DOI: 10.3389/fphar.2023.1204905

Similar Assertions

The drug seemed to make more of the CD36 protein visible in the artery plaques, which might help the body clear dead cells better.

89%

The drug-treated mice had almost half as many dying cells in their artery plaques, which could mean their plaques are less damaged and more stable.

86%

The drug didn’t make the fibrous cap around the plaque thicker, so its protective effect must come from other changes, like less cell death or inflammation.

80%

The drug didn’t lower the mice’s overall cholesterol, so its benefits must come from something else—like reducing inflammation or cell death in plaques.

77%

The drug lowered two key inflammation signals in the blood by nearly half, which may help calm down the body’s harmful immune response in the arteries.

76%